Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema

Phase 1 Not yet recruiting 60 enrolled Laboratorios Sophia S.A de C.V.

NaSingle-groupOpen-labelTreatment

Summary

Phase I, prospective, interventional, open-label, multicenter clinical trial to evaluate the safety of intravitreal PRO-169 through the presence of serum anti-drug antibodies (ADAs) to bevacizumab.

Timeline

Start: 2026-03-01
Primary completion: 2026-12-15
Completion: 2026-12-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	1.25 mg	Intravitreal

Indications

No indication recorded.